You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
A huge toll of illness and death, a dire need for new treatments, and rapid scientific progress are inspiring researchers to battle malaria. But most drug companies balk at investing in what they see as a Third World disease. Some researchers think it's time for the government to step in, perhaps with tax breaks and longer patents for certain drugs on the condition that the revenue be used for new antimalarials.